# Amycretin Beginner's Guide: Novo's GLP-1 + Amylin Dual Agonist
> Note: PeptIQ is not a medical provider. Amycretin is investigational. Educational content only.
Amycretin is Novo Nordisk's unimolecular GLP-1 and amylin receptor agonist. Beginners should hear that sentence as: CagriSema's two-pathway idea, rebuilt as one molecule, with oral daily and subcutaneous weekly formats heading toward Phase 3.
Why It Matters
| Idea | Beginner translation |
|---|---|
| Dual pathway in one drug | Appetite control from GLP-1 + amylin without two separate injectables |
| Oral program | Competes in the same conversation as orforglipron |
| Weekly SC program | Competes with injectable obesity drugs |
| Early large % losses | Exciting — but early cohorts are not Phase 3 proof |
Early Numbers (Orientation Only)
Public SC summaries highlighted exploratory weekly exposures including roughly 1.25 / 5 / 20 mg with mean losses scaling into the high teens / low 20%s over multi-month windows in small early studies.
Oral early work around ~50 mg daily (and higher short-term) showed double-digit loss over ~12 weeks without a clear plateau in commentary.
Phase 3 will replace these maps.
Amycretin vs CagriSema (One Line)
- CagriSema: two drugs (cagrilintide + semaglutide)
- Amycretin: one dual agonist molecule
What to Track
Format (oral vs SC), dose step, missed doses, GI scores, protein, lifting, average weight / waist.
FAQ
Q: Is amycretin approved?
A: Not as a routine consumer therapy in this educational frame — follow Phase 3 and regulators.
Q: Is amycretin a peptide injection only?
A: No — oral and injectable programs are both in development.
Bottom Line
Amycretin is Novo's dual-pathway shortcut: one molecule, two formats, early standout signals, Phase 3 pending. Learn the architecture before memorizing milligrams.
Download PeptIQ to log oral daily or weekly injectable eras side by side.
Educational content only. Not medical advice.
